Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06186726
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2023-12-17
Brief Title:
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Sponsor:
Jian Chen
Organization:
Shanghai Proton and Heavy Ion Center
Study Overview
Official Title:
Prospective Phase II Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe the efficacy of carbon ion radiotherapy combined with chemotherapy in the treatment of inoperable locally advanced or advanced all visible lesions can be included in the radiation target area in this treatment primary thymic epithelial tumor who have no thorax radiotherapy histroy The patients will receive 72GyE18fractions of carbon ion radiotherapy Combined with platinum-containing schemes including etoposide combined with cisplatin or carboplatin or loplatin or nedaplatin paclitaxel combined with cisplatin or carboplatin or loplatin or nedaplatin etc Docetaxel combined with cisplatin or carboplatin or loplatin or nedaplatin for at least 4 cycles Progression-free survival local control rate overall survival and toxicity were calculated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None